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Key Clinical Message
Insulin detemir is commonly used in obese patients with diabetes mellitus as it
is considered hepatoselective and causes less weight gain. We describe a relative
lack of effectiveness of detemir in patients with significant NAFLD and hyper-
triglyceridemia, compared to isophane insulin. This may affect how such
patients are managed with insulin.
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Background
Insulin detemir has now become established as an effec-
tive basal insulin preparation and is widely used in the
management of both type 1 and type 2 diabetes. Although
it is similar in efficacy to isophane insulin, we have
observed a relative lack of efficacy in two patients with
significant hypertriglyceridemia and established nonalco-
holic fatty liver disease, suggesting that there are circum-
stances where the efficacy of detemir may be adversely
affected by specific metabolic parameters.
Case Report
Patient 1 was a 56-year-old Caucasian man with a 4-year
history of poorly controlled type 2 diabetes and marked
hypertriglyceridemia (random triglycerides were
28.7 mmol/L and total cholesterol was 7.9 mmol/L at
diagnosis). His mother had type 2 diabetes, but there was
no other family history of note. He denied alcohol con-
sumption for the previous 14 years and had been only a
light drinker previously. At the time of starting insulin he
was being treated with metformin, gliclazide, fenofibrate,
and omacor.
On examination, he was obese with a body weight of
109 kg and BMI of 32 kg/m2. He had eruptive
xanthomata and evidence of splenomegaly but no hep-
atomegaly. Glycated hemoglobin (HbA1c) was 69 mmol/
mol (8.5%), fasting triglycerides 8.4 mmol/L, and total
cholesterol 4.5 mmol/L. Serum creatinine was 110 lmol/L
(eGFR 102 mL/min/1.73 m2) and liver enzymes were
slightly elevated: AST 71 iU/L (ref 10–50) and cGT
60 iU/L (1–55). Serum albumin was normal 47 g/dL (35–
50), INR 1.04, and hepatitis serology was negative. Ultra-
sound confirmed a 17.7-cm spleen and CT demonstrated
nonalcoholic fatty liver disease (NAFLD). In view of sple-
nomegaly, he underwent a bone marrow aspirate and tre-
phine biopsy, both of which were normal. A liver biopsy
confirmed hepatosteatosis with marked steatosis, mild
inflammatory activity, and hepatocellular ballooning
(Fig. 1A). In part of the biopsy, bridging fibrosis with
parenchymal nodule formation was in keeping with cir-
rhotic transformation (Fig. 1B).
Insulin detemir (14 units nocte) was commenced as his
random glucose values were 17–22 mmol/L. The dose was
rapidly titrated upward. Within five months he was using
158 units per day of detemir, in divided doses, plus insu-
lin aspart 24 units with each meal. Despite these doses,
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his capillary glucose values were consistently more than
10 mmol/L and HbA1c remained unsatisfactory at
69 mmol/mol (8.5%). Basal insulin was then changed to
insulatard 70 units per day in divided doses (insulin
aspart dose unchanged) and within four months his
HbA1c had fallen to 51 mmol/mol (6.8%) and by
12 months he had lost 6 kg of weight.
Patient 2 was a 68-year-old man with a 20-year history
of type 2 diabetes and type V hyperlipidemia. For
two years, after the diagnosis of diabetes, he was managed
with oral hypoglycemic agents alone. He then developed
necrotizing pancreatitis (considered secondary to hyper-
triglyceridemia) and was treated with human isophane
insulin and human soluble insulin for ten years before
being switched to detemir and novorapid. He was referred
due to the patient’s concern of escalating insulin dose
and associated weight gain of 20 kg over the previous
five years. At the time of referral the detemir dose was
120 units twice daily and novorapid 120 units with each
meal (total of 600 units/day). HbA1c was 55 mmol/mol
(7.2%). He did not drink alcohol.
On examination he was obese with body weight of
126 kg and BMI of 44.6 kg/m2. Random triglycerides
were markedly elevated (31.9 mmol/L), total cholesterol
was 6.3 mmol/L, and HDL was 0.3 mmol/L. There was
no clinical or biochemical evidence of any endocrinopa-
thy to explain insulin resistance and no evidence of
immune-mediated insulin resistance. Liver enzymes and
synthetic function were normal but there was mild renal
impairment (serum creatinine 145 lmol/L; eGFR 77
mL/min/1.73 m2). Liver ultrasound showed extensive fat
infiltration consistent with NAFLD. Detemir was changed
to isophane insulin 100 units BD and novorapid reduced
to 100 units/meal. After six months, the dose of insu-
latard had stabilized at 140 units BD and Novorapid 50
units TDS (430 units/day – 30% reduction in total daily
dose), his weight remained unchanged and despite the
reduction in insulin dose, HbA1c improved to 50 mmol/
mol (6.7%).
Discussion
The two cases presented in this report showed that in
patients with a history of severe hypertriglyceridemia and
significant fat infiltration of the liver, a hepatoselective
insulin (detemir) appeared less efficacious in achieving
glycemic control. Very high insulin doses were required
and weight gain was problematic.
Insulin detemir differs from human insulin by the dele-
tion of the amino acid threonine in position 30 of the B
chain, plus the addition of a C14 fatty acid chain at posi-
tion 29 of the B chain. This allows detemir to reversibly
bind to serum albumin [1] and is a characteristic that has
led to it being considered a hepatoselective insulin: the
albumin–insulin molecule is unable to pass through the
capillary endothelial cell barrier to reach peripheral adipo-
cytes, whereas in the liver, the albumin–detemir molecule
is able to pass freely through the sinusoids. This allows it
to exert a greater effect on hepatocytes than in peripheral
tissues [2].
Hypothetically, the efficacy of hepatoselective insulin
may be reduced in NAFLD by less hepatic exposure to
insulin (due to increased insulin clearance or to portosys-
temic shunting), or from direct hepatic parenchymal cell
damage. Given that the usual action of insulin is to stim-
ulate the liver to store glucose in the form of glycogen
and to switch off gluconeogenesis, underexposure of hep-
atocytes to insulin would lead to hyperglycemia.
A portosystemic shunt was thought to be unlikely in
these patients as there were no radiological features of
collateral (variceal) circulation. Increased clearance of
(A)
(B)
Figure 1. (A) Liver with marked steatosis and hepatocellular
ballooning (H&E). (B) Reticulin stain (Gordon and Sweet) reveals, in
part of the biopsy core, bridging fibrosis with parenchymal nodule
formation in keeping with cirrhotic transformation.
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detemir might have occurred; premarketing studies sug-
gested that hepatic impairment affected the bioavailability
of insulin. In these studies there was a 35–47% faster
clearance of detemir in patients with severe/moderate
liver insufficiency as compared to healthy subjects [3]. By
contrast, clearance of human insulin is usually reduced in
liver failure [4] and insulin clamp studies with human
insulin have shown decreased clearance in patients with
fat infiltration of the liver [5].
In a mouse model of NAFLD (induced by high-fat feed-
ing), there was decreased insulin activation of glycogen
synthase and increased gluconeogenesis [6] during a eug-
lycemic–hyperinsulinemic clamp, suggesting a direct,
adverse consequence of hepatic fat accumulation. There
are no equivalent data for human NAFLD. The closest
model available is of detemir’s action in obesity where the
presence of NAFLD may be inferred [7]. A pharmacody-
namic study of 18 subjects showed that in the presence of
Grade 1 obesity (BMI 30–35 kg/m2) a lower glucose infu-
sion rate was required to maintain normoglycemia after
administration of detemir, compared to Neutral Protamine
Hagedorn (NPH) insulin or glargine [8]. This suggests
reduced efficacy in obesity. However, it was not reported
whether the participants in this study had NAFLD.
Advanced hepatocellular fibrosis may be associated with a
change in the configuration of the sinusoidal endothelium,
including loss of fenestrations, which would reduce the
exchanges between hepatocytes and sinusoidal blood.
Therefore, this would suggest that in severe NAFLD/cir-
rhosis, higher doses of detemir insulin would be required.
An alternative hypothesis is that hypertriglyceridemia
may have a direct, adverse effect on detemir action. The
binding of detemir to albumin could be affected by the
lipid content of plasma. Competition experiments with
fatty acids have shown that levemir can be displaced from
human albumin by long-chain fatty acids (containing at
least 12 carbon atoms) but with much weaker competi-
tion by a medium chain fatty acid [9]. The significance of
this is uncertain, but potentially it could lead to loss
of biological activity, or unpredictable release or clearance
of levemir.
Detemir-specific insulin antibodies were not measured
in the two cases. Antibody development has been
observed in phase 3 clinical trials of detemir, but did not
impact on metabolic control [10].
Hypertriglyceridemia and NAFLD in these cases were
attributed to insulin resistance secondary to obesity. There
were no specific features of alternative cause(s) for a rela-
tive lack of efficacy of insulin, such as lysosomal storage
disease or monogenic insulin resistance syndromes - and
these were not tested for. It is possible that the cases
described relate to less common etiologies of insulin
resistance.
In managing patients with diabetes, interindividual dif-
ferences in response to insulin may be encountered; a rel-
ative lack of efficacy with one type of insulin may not be
seen with an alternative insulin. Such a response may be
unrelated to the degree of hepatoselectivity of the insulin
chosen.
In conclusion, these two cases suggest that detemir may
be less efficacious in patients with significant hypertriglyc-
eridemia complicated by NAFLD. It is not possible to
determine a precise mechanism to explain this observa-
tion but this could be due primarily to hypertriglyc-
eridemia or due to the effects of infiltration of hepatic
parenchyma with lipid.
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